Cancer Treatment Reviews
Volume 27, Issue 6 , Pages 351-363 , December 2001

Continuing therapy for childhood acute lymphoblastic leukaemia: clinical and cellular pharmacology of methotrexate, 6-mercaptopurine and 6-thioguanine

References 

  1. Simone JV. Optimal current treatment of childhood acute lymphoblastic leukaemia. Cancer Treat Rep. 1981;65:97–100
  2. Chessells JM, Bailey C, Richards SM. Intensification of treatment and survival in all children with lymphoblastic leukaemia: Results of UK Medical Research Council trial UKALL X. Lancet. 1995;345:143–148
  3. Pui C-H, Hazem H, Mahmoud H, Rivera GK, Hancock ML, Sandland JT, et al. Early intensification of intrathecal chemotherapy virtually eliminates central nervous system relapse in children with acute lymphoblastic leukaemia. Blood. 1998;92:411–415
  4. Bleyer WA, Sather HN, Noickerson HU, Coocia PF, Miller DR, Littman PS, et al. Monthly pulses of vincristine and prednisone prevent bone marrow and testicular relapse in low-risk childhood acute lymphoblastic leukaemia: a report of the CCG-161 study by the Children's Cancer Study Group. J Clin Oncol. 1991;9:1012–1021
  5. Veerman A JP, Hahlen K, Kamps WA, Van Leeuwen EF, DE vaan G AM, Solbu G, et al. High cure rate with a moderately intensive treatment regimen in non-high-risk childhood acute lymphoblastic leukaemia: Results of protocol ALL VI form the Dutch Childhood Leukaemia Study Group. J Clin Oncol. 1996;14:911–918
  6. Mahoney DH, Shuster J, Nitschke R, Lauer SJ, Winick N, Steuber CP, et al. Intermediate-dose intravenous methotrexate with intravenous mercaptopurine is superior to repetitive low-dose oral methotrexate with intravenous mercaptopurine for children with lower-risk B-lineage acute lymphoblastic leukaemia: A Pediatric Oncology Group Phase III trial. J Clin Oncol. 1998;16:246–254
  7. Land VJ, Shuster WM, Crist Y, Ravindranath Y, Harris MB, Krance RA, et al. Comparison of two schedules of intermediate-dose methotrexate and cytarabine consolidation therapy for childhood B-precursor cell acute lymphoblastic leukaemia; a Pediatric Oncology Group study. J Clin Oncol. 1994;12:1939–1945
  8. Nachman JB, Sather HN, Sensel MG, Trigg ME, Cherlow JM, Lukens JN, et al. Augmented post-induction therapy for children with high-risk acute lymphoblastic leukaemia and a slow response to initial therapy. N Engl J Med. 1998;338:1663–1671
  9. Eden OB, Lilleyman JS, Richards S, Shaw MP, Peto J. Results of Medical Research Council Childhood Leukaemia Trial UKALL VIII (Report to the Medical Research Council on behalf of the Working Party on Leukaemia in Childhood). Br J Haematol. 1991;78:187–196
  10. Elion GB. The purine path to chemotherapy. Science. 1989;244:41–47
  11. Natsumeda Y, Prajda N, Donohue JP, Glover JL, Weber G. Enzymic capacities of purine de novo and salvage pathways for nucleotide synthesis in normal and neoplastic tissues. Cancer Res. 1984;44:2475–2479
  12. Schimandle CM, Mole LA, Sherman IW. Purification of hypoxanthine-guanine phosphoribosyltransferase of Plasmodium lophurae. Mol Biochem Parasitol. 1987;23:39–45
  13. Krynetski EY, Krynetskaia NF, Yanishevski Y, Evans WE. Methylation of mercaptopurine, thioguanine, and their nucleotide metabolites by heterologously expressed human thiopurine S-methyltransferase. Mol Pharmacol. 1995;47:1141–1147
  14. Tay BS, Lilley R MC, Murray AW, Atkinson MR. Inhibition of phosphoribosyl pyrophosphate amidotransferase form Erlich ascites-tumour cells by thiopurine nucleotides. Biochem Pharmacol. 1968;18:936–938
  15. Shi RZ, Lyons SD, Christopherson RI. Metabolic effects of thiopurine derivatives against human CCRF-CEM leukaemia cells. Int J Biochem Cell Biol. 1998;30:885–895
  16. Hande KR, Garrow GC. Purine antimetabolites. In:  Chabner BA,  Longo DL editor. Cancer Chemotherapy and Biotherapy: Principle and Practice. 2nd Edn. Philadelphia: JB Lippincott & Company; 1996;p. 235–252
  17. Zimm S, Johnson GE, Chabner BA, Poplack DG. Cellular pharmacokinetics of mercaptopurine in human neoplastic cells and cell lines. Cancer Res. 1985;45:4156–4161
  18. Pieters R, Huismans DR, Loonen AH, Peters GJ, Hahlen K, van der Does-van den Berg A, et al. Relation of 5′-nucleotidase and phosphatase activities with immunophenotype, drug resistance and clinical prognosis in childhood leukaemia. Leukaemia Res. 1992;16:873–880
  19. Ling YH, Chan JY, Beattie KL, Nelson JA. Consequences of 6-thioguanine incorporation into DNA on polymerase, ligase and endonuclease function. Mol Pharmacol. 1992;42:802–807
  20. Fink D, Aebi S, Howell SB. The role of DNA mismatch repair in drug resistance. Clin Cancer Res. 1998;4:1–6
  21. Stet EH, De Abreu RA, Bokkerink JP, Lambooy LH, Vogels-Mentink TM, Keizer-Gerritsen JJ, et al. Reversal of methylmercaptopurine cytotoxicity by purine ribonucleotides and adenine. Biochem Pharmacol. 1995;49:49–56
  22. Morgan CJ, Chawdry RN, Smith AR, Stravo-Sagraves G, Trewyn RW. 6-thioguanine-induced growth arrest in 6-mercaptopurine-resistant human leukaemia cells. Cancer Res. 1994;54:5387–5393
  23. Tidd DM, Paterson A RP. A biochemical mechanism for the delayed cytotoxic reaction of 6-mercaptopurine. Cancer Res. 1974;34:738–746
  24. Adamson PC, Poplack DG, Balis FM. The cytotoxicity of thioguanine versus mercaptopurine in acute lymphoblastic leukaemia. Leukaemia Res. 1994;18:805–810
  25. da Silva CP, de Olivera CR, De Lima M. Apoptosis as a mechanism of cell death induced by different chemotherapeutic drugs in human leukaemic T-lymphocytes. Biochem Pharmacol. 1996;51:1331–1340
  26. Adamson PC, Balis FM, Hawkins ME, Murphy RF, Poplack DG. Desulfuration of 6-mercaptopurine: The basis for the paradoxical cytotoxicity of thiopurines in cultured human leukaemic cells. Biochem Pharmacol. 1993;46:1627–1636
  27. Klumper E, Pieters R, Veerman AJ, Huismans DR, Loonen AH, Hahlen K, et al. In vitro. cellular drug resistance in children with relapsed/refractory acute lymphoblastic leukaemia.;86:3861–3868
  28. Adamson PC, Poplack DG, Balis FM. The cytotoxicity of thioguanine versus mercaptopurine in acute lymphoblastic leukaemia. Leukaemia Res. 1994;18:805–810
  29. Warren DJ, Andersen A, Slordal L. Quantitation of 6-thioguanine residues in peripheral blood leukocyte DNA obtained from patients receiving 6-mercaptopurine-based continuing therapy. Cancer Res. 1995;55:1670–1674
  30. Krynetski EY, Tai HL, Yates CR, Fessing MY, Loennechen T, Schuetz JD, et al. Genetic polymorphism of thiopurine S-methyltransferase: clinical importance and molecular mechanisms. Pharmacogenetics. 1996;6:279–290
  31. Otterness D, Szumlanski C, Lennard L, Klemetsdal B, Aarbakke J, Park-Hah JO, et al. Human thiopurine methyltransferase pharmacogenetics: gene sequence polymorphisms. Clin Pharmacol Ther. 1997;62:60–73
  32. Lennard L, Welch JC, Lilleyman JS. Thiopurine drugs in the treatment of childhood leukaemia: the influence of inherited thiopurine methyltransferase activity on drug metabolism and cytotoxicity. Br J Clin Pharmacol. 1997;44:455–461
  33. Erb N, Harms DO, Janka-Schaub G. Pharmacokinetics and metabolism of thiopurines in children with acute lymphoblastic leukaemia receiving 6-thioguanine versus 6-mercaptopurine. Cancer Chemother Pharmacol. 1998;42:266–272
  34. Lennard L, Ken D, Lilleyman JS. Oral 6-mercaptopurine in childhood leukaemia: Parent drug pharmacokinetics and active metabolite concentrations. Clin Pharmacol Ther. 1986;40:287–292
  35. Lennard L, Lilleyman JS. Varaible mercaptopurine metabolism and risk of relapse in childhood acute lymphoblastic leukaemia. J Clin Oncol. 1989;7:1816–1823
  36. Lennard L, Welch JC, Lilleyman JS. Thiopurine drugs in the treatment of childhood leukaemia: the influence of inherited thiopurine methyltransferase activity on drug metabolism and cytotoxicity. Br J Clin Pharmacol. 1997;44:455–461
  37. McLeod HL, Relling MV, Liu G, Pui C-H, Evans WE. Polymorphic thiopurine methyltransferase in erythrocytes is indicative of activity in leukaemic blasts from children with acute lymphoblastic leukaemia. Blood. 1995;85:1897–1902
  38. Allegra CJ. Antifolates. In:  Chabner BA,  Longo DL editor. Cancer Chemotherapy and Biotherapy: Principles and Practice. Philadelphia: JB Lippincott Company; 1996;p. 109–148
  39. Curtin NJ, Harris AL, Aherne GW. Mechanism of cell death following thymidylate synthase inhibition: 2′-deoxyuridine-5′-triphosphate accumulation, DNA damage and growth inhibition following exposure to CB3717 and dipyridamole. Cancer Res. 1991;51:2346–2352
  40. Howell SB, Ensminger WD, Krishan A, Frei E. Thymidine rescue of high-dose methotrexate in humans. Cancer Res. 1978;38:325–330
  41. Takemura Y, Kobayashi H, Gibson W, Kimbell R, Miyachi H, Jackman AL. The influence of drug-exposure conditions on the development of resistance to methotrexate or ZD1694 in culture human leukaemia cells. Int J Cancer. 1996;66:29–36
  42. Galpin AJ, Scheutz JD, Mason E, Yanishevski Y, Synold TW, Barredo JC, et al. Differences in folylpolyglutamyl synthase and dihydrofolate reductase expression in human B-lineage versus T-lineage leukaemic lymphoblasts: Mechanisms for lineage differences in methotrexate polyglutamation and cytotoxicity. Mol Pharmacol. 1997;52:155–163
  43. Keefe DA, Capizzi RL, Rudnick SA. Methotrexate cytotoxicity for L5178Y/Asn− lymphoblasts: Relationship of dose and duration of exposure to tumour cell viability. Cancer Res. 1982;42:1641–1645
  44. Ohnuma T, Lo RJ, Scanlon KJ, Kamen BA, Ohnoshi T, Wolman SR, et al. Evolution of methotrexate resistance of human leukaemia cells in vitro. Cancer Res. 1985;45:1815–1822
  45. McCloskey DE, McGuire JJ, Russell CA, Rowan BG, Bertino JR, Pizzorno G, et al. Decreased folylpolyglutamate synthetase activity as a mechanism of methotrexate resistance in CCRF-CEM human leukemia sublines. J Biol Chem. 1991;266:6181–6187
  46. McGuire JJ, Heitzman KJ, Haile WH, Russell CA, McClosky DE, Piper JR. Cross resistance studies of folylpolyglutamate synthetase deficient, methotrexate resistant CCRF-CEM human leukaemia sublines. Leukaemia. 1993;7:1996–2003
  47. Barnes MJ, Estlin EJ, Taylor GA, Aherne GW, Hardcastle A, McGuire JJ, et al. The impact of polyglutamation on sensitivity to raltitrexed and methotrexate in relation to drug-induced inhibition ofde novo thymidylate and purine biosynthesis in CCRF-CEM cell lines. Clin Cancer Res. 1999;5:2548–2558
  48. Gorlick R, Goker E, Trippett T, Steinherz P, Elisseyeff Y, Mazumdar M, et al. Defective transport is a common mechanism of acquired methotrexate resistance in acute lymphoblastic leukaemia and is associated with decreased reduced folate carrier expression. Blood. 1997;89:1013–1018
  49. Matherly LH, Taub JW, Ravindranath Y, Proefke SA, Wong SC, Gimotty P, et al. Elevated dihydrofolate reductase and impaired methotrexate transport as elements in methotrexate resistance in childhood acute lymphoblastic leukaemia. Blood. 1995;85:500–509
  50. Matherly LH, Taub JW, Wong SC, Simpson PM, Ekizian R, Buck S, et al. Increased frequency of expression of elevated dihydrofolate reductase in T-cell versus B-precursor acute lymphoblastic leukaemia in children. Blood. 1997;90:578–589
  51. Whitehead VM, Rosenblatt DS, Vuchich M-J, Shuster JJ, Witte A, Beaulieu D. Accumulation of methotrexate and methotrexate polyglutamates in lymphoblasts at diagnosis of childhood acute lymphoblastic leukaemia: A pilot prognostic factor analysis. Blood. 1990;76:44–49
  52. Whitehead VM, Vuchich MJ, Lauer SJ, Mahoney D, Carroll AJ, Schuster JJ, et al. Accumulation of high levels of methotrexate polyglutamates in lymphoblasts from children with hyperdiploid (>50 chromosomes) B-lineage acute lymphoblastic leukaemia: a Pediatric Oncology Group Study. Blood. 1992;80:1316–1323
  53. Belkov VM, Krynetski EY, Scheutz JD, Yanishevski Y, Masson E, Mathew S, et al. Reduced folate carrier expression in acute lymphoblastic leukaemia, a mechanism for pliody but not lineage differences in methotrexate accumulation. Blood. 1999;93:1643–1650
  54. Goker E, Lin JT, Elisseyett Y, Tong WP, Niedzwiecki D, Tan C, et al. Decreased polyglutamation of methotrexate in acute lymphoblastic leukaemia blasts in adults compared to children with this disease. Leukaemia. 1993;7:1000–1004
  55. Giverhaug T, Loennechen T, Aarbakke J. Increased concentrations of methylated 6-mercaptopurine metabolites and 6-thioguanine nucleotides in human leukaemic cells in vitro by methotrexate. Biochem Pharmacol. 1998;55:1641–1646
  56. Guerciolini R, Szumlanski C, Weinshilboum RM. Human liver xanthine oxidase: nature and extent of individual variation. Clin Pharm Ther. 1991;50:663–672
  57. Szumlanski CL, Honchel R, Scott MC, Weinshilboum RM. Human liver thiopurine methyltransferase pharmacogenetics: biochemical properties, liver-erythrocyte correlation and presence of isoenzymes. Pharmacogenetics. 1992;2:148–159
  58. Lafolie P, Hayder S, Bjork O, Peterson C. Intra-individual variation in 6-mercaptopurine pharmacokinetics during oral continuing therapy of children with acute lymphoblastic leukaemia. Eur J Clin Pharmacol. 1991;40:599–601
  59. Kato Y, Matsushita T, Chiba K, Hijiya N, Yokoyama T, Ishizaki T. Dose-dependent kinetics of orally administered6-mercaptopurine in children with leukaemia. J Pediatrics. 1991;119:311–316
  60. Jacqz-Aigrain E, Nafa S, Medard Y, Bessa E, Lescouer B, Vilmer E. Pharmacokinetics and distribution of 6-mercaptopurine administered intravenously in children with lymphoblastic leukaemia. Eur J Clin Pharmacol. 1997;53:71–74
  61. Adamson PC, Balis FM, Arndt C, Holcenberg JS, Narang PK, Murphy RF, et al. Intrathecal 6-mercaptopurine: preclinical pharmacology, Phase I/II trial, and pharmacokinetic study. Cancer Res. 1991;51:6079–6083
  62. Balis FM, Holcenberg JS, Zimm S, Tubergen D, Collins JM, Murphy RF, et al. The effect of methotrexate on the bioavailability of oral 6-mercaptopurine. Clin Pharmacol Ther. 1987;41:384–387
  63. Evans WE, Relling M, Rodman JH, Crom WR, Boyett JM, Pui C-H. Conventional compared with individualised chemotherapy for childhood acute lymphoblastic leukaemia. N Engl J Med. 1998;338:499–505
  64. Pearson A DJ, Mills S, Amineddine HA, Long DR, Craft AW, Chessells JM. Pharmacokinetics of oral and intramuscular methotrexate in children with acute lymphoblastic leukaemia. Cancer Chemother Pharmacol. 1987;20:243–247
  65. Balis FM, Holcenberg JS, Poplack DG, Ge J, Sather HN, Murphy RF, et al. Pharmacokinetics and pharmacodynamics of methotrextare and mercaptopurine in children with lower risk acute lymphoblastic leukaemia: A joint Children's Cancer Group and Pediatric Oncology Branch study. Blood. 1998;10:3569–3577
  66. Shapiro WR, Young DG, Mehta BM. Methotrexate distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections. N Engl J Med. 1975;293:161–166
  67. Bleyer WA, Dedrick RL. Clinical pharmacology of intrathecal methotrexate. I. Pharmacokinetics in non-toxic patients after lumbar injection. Cancer Treat Rep. 1977;61:703–708
  68. Frei E, Friedreich EJ, Gehan E, Pinkel D, Holland JF, Selawry O, et al. Studies of sequential and combination antimetabolite therapy in acute leukaemia: 6-mercaptopurine and methotrexate. Blood. 1961;18:431–454
  69. Freireich EJ, Gehan E, Frei E, Schroeder LR, Wolman IJ, Anbari R, et al. The effect of 6-mercaptopurine on the duration of steroid-induced remissions in acute leukaemia: A model for evaluation of other potentially useful therapy. Blood. 1963;21:699–716
  70. Frei E, Karon M, Levin R, Freireich EJ, Taylor RJ, Hananian J. The effectivess of combinations of antileukaemic agents in inducing and maintaining remission induction in children with acute leukaemia. Blood. 1965;26:642–656
  71. Pinkerton CR, Bowman A, Holtzel H, Chessells JM. Intensive consolidation chemotherapy for acute leukaemia (UKALL X pilot study). Arch Dis Child. 1987;62:12–18
  72. Hale JP, Lilleyman JS. Importance of 6-mercaptopurine dose in lymphoblastic leukaemia. Arch Dis Child. 1991;66:462–466
  73. Welch JC, Lilleyman JS. 6-mercaptopurine dose escalation and its effect on drug tolerance in childhood acute lymphoblastic leukaemia. Cancer Chemother Pharmacol. 1996;38:113–116
  74. Relling MV, Hancock ML, Boyett JM, Pui C-H, Evans WE. Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukaemia. Blood. 1999;93:2817–2823
  75. Koren G, Ferrazini G, Sulh H, Langevin AM, Kapelushnik J, Klein J, et al. Systemic exposure to 6-mercaptopurine as a prognostic indicator in acute lymphoblastic leukaemia in children. N Engl J Med. 1990;323:17–21
  76. Pieters R, Huismans DR, Loonen AH, Peters GJ, Hahlen K, van der Does-van den Berg A, et al. Hypoxanthine-guanine phosphoribosyl-transferase in childhood leukaemia: Relation with immunophenotype, in vitro drug resistance and clinical prognosis. Int J Cancer. 1992;51:213–217
  77. Rambotti, P, Davis, S, Hypoxanthine-guanine phosphoribosyltransferase activity in normal and leukaemic lymphocytes, Br J Haematol, 49, 23, 28
  78. Coulthard SA, Howell C, Robson J, Hall AG. The relationship between thiopurine methyltransferase activity and genotype in blasts form patients with acute leukaemia. Blood. 1998;92:2856–2862
  79. Pieters R, Huismans DR, Loonen AH, Peters GJ, Hahlen K, van der Does-van den Berg A, et al. Relation of 5′-nucleotidase and phosphatase activities with immunophenotype, drug resistance and clinical prognosis in childhood leukaemia. Leukaemia Res. 1992;16:873–880
  80. Lennard L, Lilleyman JS, van Loon J, Weinshilboum RM. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia. Lancet. 1990;336:225–229
  81. Lilleyman JS, Lennard L. Mercaptopurine metabolism and risk of relapse in childhood lymphoblastic leukaemia. Lancet. 1994;343:1188–1190
  82. Frei E, Friedreich EJ, Gehan E, Pinkel D, Holland JF, Selawry O, et al. Studies of sequential and combination antimetabolite therapy in acute leukaemia: 6-mercaptopurine and methotrexate. Blood. 1961;18:431–454
  83. Goldin A, Venditti JM, Humphreys SR, Mantel N. Modification of treatment schedules in the management of advanced mouse leukaemia with amethopterin. J Natl Cancer Inst. 1956;17:203–212
  84. Acute Leukemia Group B. New treatment schedule with improved survival in childhood leukemia. JAMA. 1965;194:187–193
  85. Karon M, Freireich E, Frei E. The role of vincristine in the treatrment of childhood acute leukamia. Clin Pharm Ther. 1966;7:332–339
  86. Bostrom B, Gaynon PS, Sather H, Gold S, Hitchson RJ, Provisor A, et al. Dexamaethasone decreases central nervous system (CNS) relapse and improves event free survival in lower risk acute lymphoblastic leukaemia. Proc Am Soc Clin Oncol. 1998;17:527a
  87. Toyoda Y, Mamnabe A, Tsuchida M, Hanada R, Ikuta K, Okimoto Y, et al. Six months of maintenanace chemotherapy after intensified treatment for acute lymphoblastic leukaemia of childhood. J Clin Oncol. 2000;18:1508–1516
  88. Miller DM, Leiken SL, Albo VC, Sather H, Hammond GD. Three versus five years of continuing therapy are equivalent in childhood acute lymphoblastic leukaemia: a report from the Children's Cancer Study Group. J Clin Oncol. 1989;7:316–325
  89. Pinkel D, Hernandez K, Borella L, Holton C, Aur R, Samoy G, et al. Drug dosage and remission duration in childhood lymphocytic leukaemia. Cancer. 1971;27:247–256
  90. van Dongen J JM, Senu T, Panzer-Grumayer ER, Biondi A, Pongers-Willemse MJ, Corral L, et al. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet. 1998;352:1731–1738

PII: S0305-7372(02)90245-8

doi: 10.1053/ctrv.2002.0245

Cancer Treatment Reviews
Volume 27, Issue 6 , Pages 351-363 , December 2001

Article Tools